02:16 PM EDT, 11/01/2024 (MT Newswires) -- ESSA Pharma ( EPIX ) said late Thursday it decided to terminate the phase 2 trial evaluating the combination of masofaniten and enzalutamide in patients with metastatic castration-resistant prostate cancer compared with enzalutamide alone.

Shares slumped 71%, with intraday trading volume at over 27.6 million compared with a daily average of about 59,000.

Lexicon Pharmaceuticals ( LXRX ) said late Thursday that the Endocrinologic and Metabolic Drugs Advisory Committee of the US Food and Drug Administration voted 11-3 against recommending Zynquista (sotagliflozin) as an add-on to insulin therapy for glycemic control in adults suffering from type 1 diabetes and chronic kidney disease.

Shares sank 37% as intraday trading volume catapulted to more than 16.8 million from a daily average of about 2.7 million.

Autonomix Medical ( AMIX ) unveiled Friday the launch of a public offering of up to 698,812 common stock units at $14.31 each.

Shares retreated 24%, with intraday trading volume at over 341,000 versus a daily average of roughly 451,000.

Price: 1.52, Change: -3.68, Percent Change: -70.77